SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
F O R M 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2003
Prana Biotechnology Limited
(Name of Registrant)
Level 1, 100 Dorcas Street, South Melbourne, Victoria 3205 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F [X] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether by furnishing the information contained in
this Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): 82- ___________________
PRANA BIOTECHNOLOGY LIMITED
6-K Items
1. Prana Biotechnology Limited new issue announcement, application for
quotation of additional securities and agreement dated February 14, 2003.
ITEM 1
Appendix 3B
New issue announcement
--------------------------------------------------------------------------------
Rule 2.7, 3.10.3, 3.10.4, 3.10.5
Appendix 3B
New issue announcement,
application for quotation of additional securities
and agreement
Information or documents not available now must be given to ASX as soon as
available. Information and documents given to ASX become ASX's property and may
be made public.
Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000,
30/9/2001, 11/3/2002, 1/1/2003.
Name of entity
-------------------------------------------------------------------------------
PRANA BIOTECHNOLOGY LIMITED
-------------------------------------------------------------------------------
ABN
----------------------------
37 080 699 065
----------------------------
We (the entity) give ASX the following information.
Part 1 - All issues
You must complete the relevant sections (attach sheets if there is not enough
space).
1 +Class of +securities issued or to be -------------------------------
issued Ordinary Shares
-------------------------------
2 Number of +securities issued or to --------------------------------
be issued (if known) or maximum 499,403
number which may be issued --------------------------------
3 Principal terms of the +securities (eg, -------------------------------
if options, exercise price and expiry Pari passu with existing quoted
date; if partly paid +securities, the ordinary shares
amount outstanding and due dates for --------------------------------
payment; if +convertible securities,
the conversion price and dates for
conversion)
--------------------------------------------------------------------------------
+ See chapter 19 for defined terms.
1/1/2003 Appendix 3B Page 1
Appendix 3B
New issue announcement
--------------------------------------------------------------------------------
4 Do the +securities rank equally in all -------------------------------
respects from the date of allotment Yes
with an existing +class of quoted -------------------------------
+securities?
If the additional securities do not
rank equally, please state:
- the date from which they do
- the extent to which they
participate for the next dividend,
(in the case of a trust,
distribution) or interest payment
- the extent to which
they do not rank equally, other than in relation
to the next dividend,
distribution or interest payment
5 Issue price or consideration -------------------------------
$0.50 per share
-------------------------------
6 Purpose of the issue -------------------------------
(If issued as consideration for the Exercise of Options
acquisition of assets, clearly identify
those assets) To be used for Working Capital
Purposes
-------------------------------
7 Dates of entering +securities into -------------------------------
uncertificated holdings or 14/2/03
despatch of certificates -------------------------------
--------------- ---------------
8 Number and +class of all +securities Number +Class
quoted on ASX (including the --------------- ----------------
securities in clause 2 if applicable) 59,618,869(PBT) Ordinary Shares
6,488,434 (PBTO) Options exercisable
at $0.50 on or
before 1 March 2003
--------------- --------------------
--------------------------------------------------------------------------------
+ See chapter 19 for defined terms.
Appendix 3B Page 2 1/1/2003
Appendix 3B
New issue announcement
--------------------------------------------------------------------------------
----------------------------- -------------------------
Number +Class
----------------------------- -------------------------
9 Number and +class of all +securities 20,150,000 (PBTAK) Options exercisable
not quoted on ASX (including the at $0.50 on or
securities in clause 2 if applicable) before 1 December
2004.
200,000 (PBTAM) Options exercisable
at $0.50 on or before
20 March 2004.
Employee &
410,000 (PBTAO) Consultants Options
exercisable at $0.50
on or before 30 June
2005.
200,000 (PBTAQ) Options exercisable
at $0.50 on or
before 1 October
2005.
----------------------------- --------------------------
10 Dividend policy (in the case of a -------------------------------
trust, distribution policy) on the Unchanged
increased capital (interests) -------------------------------
Part 2 - Bonus issue or pro rata issue
11 Is security holder approval -------------------------------
required?
-------------------------------
12 Is the issue renounceable or non- -------------------------------
renounceable?
-------------------------------
13 Ratio in which the +securities will be -------------------------------
offered
-------------------------------
14 +Class of +securities to which the -------------------------------
offer relates
-------------------------------
15 +Record date to determine -------------------------------
entitlements
16 Will holdings on different registers -------------------------------
(or subregisters) be aggregated for
calculating entitlements?
-------------------------------
17 Policy for deciding entitlements in -------------------------------
relation to fractions
-------------------------------
--------------------------------------------------------------------------------
+ See chapter 19 for defined terms.
1/1/2003 Appendix 3B Page 3
Appendix 3B
New issue announcement
--------------------------------------------------------------------------------
18 Names of countries in which the -------------------------------
entity has +security holders who will
not be sent new issue documents
Note: Security holders must be told how their
entitlements are to be dealt with.
Cross reference: rule 7.7. -------------------------------
19 Closing date for receipt of -------------------------------
acceptances or renunciations
-------------------------------
20 Names of any underwriters -------------------------------
-------------------------------
21 Amount of any underwriting fee or -------------------------------
commission
-------------------------------
22 Names of any brokers to the issue -------------------------------
23 Fee or commission payable to the -------------------------------
broker to the issue
-------------------------------
24 Amount of any handling fee ------------------------------
payable to brokers who lodge
acceptances or renunciations on
behalf of +security holders -------------------------------
25 If the issue is contingent on -------------------------------
+security holders' approval, the date
of the meeting -------------------------------
26 Date entitlement and acceptance -------------------------------
form and prospectus or Product
Disclosure Statement will be sent to
persons entitled -------------------------------
27 If the entity has issued options, -------------------------------
and the terms entitle option holders to
participate on exercise, the date on
which notices will be sent to option
holders -------------------------------
28 Date rights trading will begin (if -------------------------------
applicable)
-------------------------------
29 Date rights trading will end (if -------------------------------
applicable)
-------------------------------
30 How do +security holders sell their -------------------------------
entitlements in full through a broker?
------------------------------
--------------------------------------------------------------------------------
+See chapter 19 for defined terms.
Appendix 3B Page 4 1/1/2003
Appendix 3B
New issue announcement
-------------------------------------------------------------------------------
31 How do +security holders sell part --------------------------------
of their entitlements through a broker
and accept for the balance?
--------------------------------
32 How do +security holders dispose --------------------------------
of their entitlements (except by sale
through a broker)? --------------------------------
33 +Despatch date --------------------------------
--------------------------------
Part 3 - Quotation of securities
You need only complete this section if you are applying for quotation of
securities
34 Type of securities
(tick one)
(a) [X} Securities described in Part 1
(b) [ ] All other securities
Example: restricted securities at the end of the escrowed
period, partly paid securities that become fully paid,
employee incentive share securities when restriction ends,
securities issued on expiry or conversion of convertible
securities
Entities that have ticked box 34(a)
Additional securities forming a new class of securities
Tick to indicate you are providing the information or
documents
35 [ ] If the +securities are +equity securities, the names of the 20
largest holders of the additional +securities, and the number
and percentage of additional +securities held by those holders
36 [ ] If the +securities are +equity securities, a distribution
schedule of the additional +securities setting out the number
of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over
37 [ ] A copy of any trust deed for the additional +securities
--------------------------------------------------------------------------------
+ See chapter 19 for defined terms.
1/1/2003 Appendix 3B Page 5
Appendix 3B
New issue announcement
--------------------------------------------------------------------------------
Entities that have ticked box 34(b)
38 Number of securities for which ------------------------------
+quotation is sought
------------------------------
39 Class of +securities for which ------------------------------
quotation is sought
------------------------------
40 Do the +securities rank equally ------------------------------
in all respects from the date of
allotment with an existing +class of
quoted +securities? ------------------------------
If the additional securities do not ------------------------------
rank equally, please state:
- the date from which they do
- the extent to which they participate
for the next dividend, (in
the case of a trust, distribution)
or interest payment
- the extent to which
they do not rank equally, other than
in relation to the next dividend,
distribution or interest payment
------------------------------
41 Reason for request for quotation ------------------------------
now
Example: In the case of restricted securities,
end of restriction period
(if issued upon conversion of
another security, clearly identify that
other security) ------------------------------
----------------- ------------
Number +Class
----------------- ------------
42 Number and +class of all
+securities quoted on ASX
(including the
securities in clause 38)
----------------- ------------
--------------------------------------------------------------------------------
+ See chapter 19 for defined terms.
Appendix 3B Page 6 1/1/2003
Appendix 3B
New issue announcement
--------------------------------------------------------------------------------
Quotation agreement
1 +Quotation of our additional +securities is in ASX's absolute discretion.
ASX may quote the +securities on any conditions it decides.
2 We warrant the following to ASX.
- The issue of the +securities to be quoted complies with the law and is
not for an illegal purpose.
- There is no reason why those +securities should not be granted
+quotation.
- An offer of the +securities for sale within 12 months after their
issue will not require disclosure under section 707(3) or section
1012C(6) of the Corporations Act.
Note: An entity may need to obtain appropriate warranties from
subscribers for the securities in order to be able to give this
warranty
- Section 724 or section 1016E of the Corporations Act does not apply to
any applications received by us in relation to any +securities to be
quoted and that no-one has any right to return any +securities to be
quoted under sections 737, 738 or 1016F of the Corporations Act at the
time that we request that the +securities be quoted.
- We warrant that if confirmation is required under section 1017F of the
Corporations Act in relation to the +securities to be quoted, it has
been provided at the time that we request that the +securities be
quoted.
- If we are a trust, we warrant that no person has the right to return
the +securities to be quoted under section 1019B of the Corporations
Act at the time that we request that the +securities be quoted.
--------------------------------------------------------------------------------
+ See chapter 19 for defined terms.
1/1/2003 Appendix 3B Page 7
Appendix 3B
New issue announcement
--------------------------------------------------------------------------------
3 We will indemnify ASX to the fullest extent permitted by law in respect of
any claim, action or expense arising from or connected with any breach of
the warranties in this agreement.
4 We give ASX the information and documents required by this form. If any
information or document not available now, will give it to ASX before
+quotation of the +securities begins. We acknowledge that ASX is relying on
the information and documents. We warrant that they are (will be) true and
complete.
Sign here: /s/Richard Revelins Date: 14 February 2003
(Director/Company secretary)
Print name: RICHARD REVELINS
== == == == ==
-------------------------------------------------------------------------------
+ See chapter 19 for defined terms.
Appendix 3B Page 8 1/1/2003
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
PRANA BIOTECHNOLOGY LIMITED
---------------------------
(Registrant)
By: /s/Phillip Hains
-------------------------------
Phillip Hains
Administrative Officer
Date: February 20, 2003